Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

References for PMC Articles for PubMed (Select 14586044)

1.

Therapy for chronic obstructive pulmonary disease in the 21st century.

Donnelly LE, Rogers DF.

Drugs. 2003;63(19):1973-98. Review.

PMID:
12962514
2.

Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease.

Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, Barnes PJ.

Am J Respir Crit Care Med. 2003 Jan 1;167(1):24-31. Epub 2002 Sep 17.

PMID:
12406856
3.

New concepts in chronic obstructive pulmonary disease.

Barnes PJ.

Annu Rev Med. 2003;54:113-29. Epub 2001 Dec 3. Review.

PMID:
12359824
4.

Cancer chemopreventive activity of resveratrol.

Bhat KP, Pezzuto JM.

Ann N Y Acad Sci. 2002 May;957:210-29. Review.

PMID:
12074974
5.

Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease.

Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ.

Am J Respir Cell Mol Biol. 2002 May;26(5):602-9.

PMID:
11970913
6.

Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production.

Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC.

Biochem Pharmacol. 2001 Nov 1;62(9):1299-308.

PMID:
11705464
7.

Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts.

Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz HG, Daniel PT, Henze G.

Leukemia. 2001 Nov;15(11):1735-42.

PMID:
11681415
8.

Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage.

Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A.

Mutat Res. 2001 Sep 20;496(1-2):171-80.

PMID:
11551493
9.
10.

The world of resveratrol.

Soleas GJ, Diamandis EP, Goldberg DM.

Adv Exp Med Biol. 2001;492:159-82. Review. No abstract available.

PMID:
11480664
11.

Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT.

Ekberg-Jansson A, Andersson B, Bake B, Boijsen M, Enanden I, Rosengren A, Skoogh BE, Tylén U, Venge P, Löfdahl CG.

Respir Med. 2001 May;95(5):363-73.

12.

Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease.

Culpitt SV, Rogers DF.

Expert Opin Pharmacother. 2000 Jul;1(5):1007-20. Review.

PMID:
11249492
13.
15.
16.

Biological effects of resveratrol.

Frémont L.

Life Sci. 2000 Jan 14;66(8):663-73. Review.

PMID:
10680575
17.

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP; Lung Health Study Research Group.

Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381-90.

PMID:
10673175
18.

Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease.

Barnes PJ.

Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):342-4; discussioin 344. No abstract available.

PMID:
10673166
19.

Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease.

Calverley PM.

Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):341-2; discussion 344. No abstract available.

PMID:
10673165
20.

Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity.

Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, Savouret JF.

Mol Pharmacol. 1999 Oct;56(4):784-90.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk